These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38784024)

  • 1. Utilization of Romosozumab in Primary Care.
    Hye Yang S; Mittal N; Bell AL; Bell CE
    J Pharm Technol; 2024 Jun; 40(3):152-157. PubMed ID: 38784024
    [No Abstract]   [Full Text] [Related]  

  • 2. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
    Nealy KL; Harris KB
    Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
    Huang W; Nagao M; Yonemoto N; Guo S; Tanigawa T; Nishizaki Y
    Pharmacoepidemiol Drug Saf; 2023 Jun; 32(6):671-684. PubMed ID: 36703260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
    Langdahl BL; Libanati C; Crittenden DB; Bolognese MA; Brown JP; Daizadeh NS; Dokoupilova E; Engelke K; Finkelstein JS; Genant HK; Goemaere S; Hyldstrup L; Jodar-Gimeno E; Keaveny TM; Kendler D; Lakatos P; Maddox J; Malouf J; Massari FE; Molina JF; Ulla MR; Grauer A
    Lancet; 2017 Sep; 390(10102):1585-1594. PubMed ID: 28755782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
    Cosman F; Lewiecki EM; Ebeling PR; Hesse E; Napoli N; Matsumoto T; Crittenden DB; Rojeski M; Yang W; Libanati C; Ferrari S
    J Bone Miner Res; 2020 Jul; 35(7):1333-1342. PubMed ID: 32445228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
    Brown JP; Engelke K; Keaveny TM; Chines A; Chapurlat R; Foldes AJ; Nogues X; Civitelli R; De Villiers T; Massari F; Zerbini CAF; Wang Z; Oates MK; Recknor C; Libanati C
    J Bone Miner Res; 2021 Nov; 36(11):2139-2152. PubMed ID: 34190361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
    Miller PD; Adachi JD; Albergaria BH; Cheung AM; Chines AA; Gielen E; Langdahl BL; Miyauchi A; Oates M; Reid IR; Santiago NR; Vanderkelen M; Wang Z; Yu Z
    J Bone Miner Res; 2022 Aug; 37(8):1437-1445. PubMed ID: 35466448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T; Hijikata Y; Matsubara Y; Watanabe N
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
    Lau EMC; Dinavahi R; Woo YC; Wu CH; Guan J; Maddox J; Tolman C; Yang W; Shin CS
    Osteoporos Int; 2020 Apr; 31(4):677-685. PubMed ID: 32047951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis.
    Hartz MC; Johannessen FB; Harsløf T; Langdahl BL
    J Clin Endocrinol Metab; 2024 Jul; ():. PubMed ID: 39011972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
    Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
    Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.
    Kaveh S; Hosseinifard H; Ghadimi N; Vojdanian M; Aryankhesal A
    Clin Rheumatol; 2020 Nov; 39(11):3261-3276. PubMed ID: 32385757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.